Review





Similar Products

abt737  (MedChemExpress)
95
MedChemExpress abt737
Abt737, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abt737/product/MedChemExpress
Average 95 stars, based on 1 article reviews
abt737 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
abt 737  (MedChemExpress)
95
MedChemExpress abt 737
(A) Representative high-content images of Cal51 mScarlet-MDM2 wild-type (WT) and CEP83 -/- cells treated with DMSO or ZM, and of Cal51 mScarlet-MDM2 WT cells treated with ZM in the presence of increasing concentrations of Emricasan. Nuclear mScarlet fluorescence is displayed as binary labeling: nuclei exceeding a predefined fluorescence threshold are pseudo-colored in yellow, whereas nuclei below threshold are shown in blue. Scale bar: 200 μm. (B) Representative high-content images of Cal51 cells treated with staurosporine <t>(STS),</t> <t>ABT-737</t> (ABT), or the combined treatment (STS + ABT), in the presence of increasing concentrations of Emricasan. Effector caspase activity was assessed using the CellEvent reporter and is displayed as binary nuclear labeling, with CellEvent-positive nuclei shown in yellow and negative nuclei in blue. Scale bar: 200 μm. (C) Dose-response curves for six caspase inhibitors (Emricasan, QVD, LJ2a, LJ3a, LJ3b, and Belnacasan) measured using two high-content assays performed under distinct treatment conditions. Nuclear mScarlet fluorescence was quantified in Cal51 mScarlet-MDM2 cells treated with ZM, whereas effector caspase activity was quantified in Cal51 cells treated with STS + ABT using the CellEvent reporter. Data represent 3 biological replicates, each with 3 technical replicates (n = 9). (D) Table summarizing IC 50 values for the indicated caspase inhibitors obtained from the two assay conditions shown in (C). ND, not determined. (E) Immunoblot analysis of Cal51 cells treated with ZM or with STS + ABT in the presence of vehicle (DMSO), Emricasan, QVD, or LJ2a (10 μM each).
Abt 737, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/abt 737/product/MedChemExpress
Average 95 stars, based on 1 article reviews
abt 737 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
hy 15763 abt 737 medchemexpress  (MedChemExpress)
97
MedChemExpress hy 15763 abt 737 medchemexpress
(A) Representative high-content images of Cal51 mScarlet-MDM2 wild-type (WT) and CEP83 -/- cells treated with DMSO or ZM, and of Cal51 mScarlet-MDM2 WT cells treated with ZM in the presence of increasing concentrations of Emricasan. Nuclear mScarlet fluorescence is displayed as binary labeling: nuclei exceeding a predefined fluorescence threshold are pseudo-colored in yellow, whereas nuclei below threshold are shown in blue. Scale bar: 200 μm. (B) Representative high-content images of Cal51 cells treated with staurosporine <t>(STS),</t> <t>ABT-737</t> (ABT), or the combined treatment (STS + ABT), in the presence of increasing concentrations of Emricasan. Effector caspase activity was assessed using the CellEvent reporter and is displayed as binary nuclear labeling, with CellEvent-positive nuclei shown in yellow and negative nuclei in blue. Scale bar: 200 μm. (C) Dose-response curves for six caspase inhibitors (Emricasan, QVD, LJ2a, LJ3a, LJ3b, and Belnacasan) measured using two high-content assays performed under distinct treatment conditions. Nuclear mScarlet fluorescence was quantified in Cal51 mScarlet-MDM2 cells treated with ZM, whereas effector caspase activity was quantified in Cal51 cells treated with STS + ABT using the CellEvent reporter. Data represent 3 biological replicates, each with 3 technical replicates (n = 9). (D) Table summarizing IC 50 values for the indicated caspase inhibitors obtained from the two assay conditions shown in (C). ND, not determined. (E) Immunoblot analysis of Cal51 cells treated with ZM or with STS + ABT in the presence of vehicle (DMSO), Emricasan, QVD, or LJ2a (10 μM each).
Hy 15763 Abt 737 Medchemexpress, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hy 15763 abt 737 medchemexpress/product/MedChemExpress
Average 97 stars, based on 1 article reviews
hy 15763 abt 737 medchemexpress - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier

Image Search Results


(A) Representative high-content images of Cal51 mScarlet-MDM2 wild-type (WT) and CEP83 -/- cells treated with DMSO or ZM, and of Cal51 mScarlet-MDM2 WT cells treated with ZM in the presence of increasing concentrations of Emricasan. Nuclear mScarlet fluorescence is displayed as binary labeling: nuclei exceeding a predefined fluorescence threshold are pseudo-colored in yellow, whereas nuclei below threshold are shown in blue. Scale bar: 200 μm. (B) Representative high-content images of Cal51 cells treated with staurosporine (STS), ABT-737 (ABT), or the combined treatment (STS + ABT), in the presence of increasing concentrations of Emricasan. Effector caspase activity was assessed using the CellEvent reporter and is displayed as binary nuclear labeling, with CellEvent-positive nuclei shown in yellow and negative nuclei in blue. Scale bar: 200 μm. (C) Dose-response curves for six caspase inhibitors (Emricasan, QVD, LJ2a, LJ3a, LJ3b, and Belnacasan) measured using two high-content assays performed under distinct treatment conditions. Nuclear mScarlet fluorescence was quantified in Cal51 mScarlet-MDM2 cells treated with ZM, whereas effector caspase activity was quantified in Cal51 cells treated with STS + ABT using the CellEvent reporter. Data represent 3 biological replicates, each with 3 technical replicates (n = 9). (D) Table summarizing IC 50 values for the indicated caspase inhibitors obtained from the two assay conditions shown in (C). ND, not determined. (E) Immunoblot analysis of Cal51 cells treated with ZM or with STS + ABT in the presence of vehicle (DMSO), Emricasan, QVD, or LJ2a (10 μM each).

Journal: bioRxiv

Article Title: Centrosome architecture and m6A-dependent gating of p53 surveillance after whole-genome doubling

doi: 10.64898/2026.02.25.707964

Figure Lengend Snippet: (A) Representative high-content images of Cal51 mScarlet-MDM2 wild-type (WT) and CEP83 -/- cells treated with DMSO or ZM, and of Cal51 mScarlet-MDM2 WT cells treated with ZM in the presence of increasing concentrations of Emricasan. Nuclear mScarlet fluorescence is displayed as binary labeling: nuclei exceeding a predefined fluorescence threshold are pseudo-colored in yellow, whereas nuclei below threshold are shown in blue. Scale bar: 200 μm. (B) Representative high-content images of Cal51 cells treated with staurosporine (STS), ABT-737 (ABT), or the combined treatment (STS + ABT), in the presence of increasing concentrations of Emricasan. Effector caspase activity was assessed using the CellEvent reporter and is displayed as binary nuclear labeling, with CellEvent-positive nuclei shown in yellow and negative nuclei in blue. Scale bar: 200 μm. (C) Dose-response curves for six caspase inhibitors (Emricasan, QVD, LJ2a, LJ3a, LJ3b, and Belnacasan) measured using two high-content assays performed under distinct treatment conditions. Nuclear mScarlet fluorescence was quantified in Cal51 mScarlet-MDM2 cells treated with ZM, whereas effector caspase activity was quantified in Cal51 cells treated with STS + ABT using the CellEvent reporter. Data represent 3 biological replicates, each with 3 technical replicates (n = 9). (D) Table summarizing IC 50 values for the indicated caspase inhibitors obtained from the two assay conditions shown in (C). ND, not determined. (E) Immunoblot analysis of Cal51 cells treated with ZM or with STS + ABT in the presence of vehicle (DMSO), Emricasan, QVD, or LJ2a (10 μM each).

Article Snippet: The following compounds were used: 2 μM ZM-447439 (MCE®, HY-10128), 1 μM Staurosporine (MCE®, HY-15141), 1 μM ABT-737 (MCE®, HY-50907), 100 nM BI2536 (MCE®, HY-50698), Nutlin-3a (MCE®, HY-10029), 20 μg/Ml Cycloheximide (Thermo Scientific Chemicals, 357420010), 10 μM 3MB-PP1 (Cayman Chemical, 17860), Belnacasan (MCE®, HY-13205), Emricasan (MCE®, HY-10396), Q-VD-OPh (MCE®, HY-12305), 2.5 μM STM2457 (Cayman Chemical, 34280), 2.5 μM ( ) or 10 μM ( ) UZH2 (TargetMol®, T40357), 2.5 μM STC-15 (MCE®, HY-156677), 2.5 μM STM3006 (MCE®, HY-156773), 1 μM NU7441 (Selleckchem, S2638), LJ2a, LJ3a and LJ3b (gift from Dr. Etienne Jacotot, Paris Cité University, Inserm).

Techniques: Fluorescence, Labeling, Activity Assay, Western Blot